LLY vs CRL
By Alex · Tickerpine
Eli Lilly and Company vs Charles River Laboratories International, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | CRL |
|---|---|---|
| Price | $1,443.50 | $337.97 |
| Market cap | $1.29T | $16.19B |
| P/E ratio | 46.9 | 367.4 |
| ROE | 86.02% | 1.27% |
| Profit margin | 31.90% | 1.01% |
| Revenue growth | 38.60% | -2.20% |
| Dividend yield | 0.48% | 0.00% |
| Beta | 0.39 | 1.34 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs CRL in plain English
- LLY is the bigger company — about 79.4× the market cap of CRL.
- LLY is cheaper on earnings (P/E 46.9 vs 367.4).
- LLY earns a higher return on equity (86% vs 1%).
- LLY is growing revenue faster (39% vs -2%).
- LLY pays a dividend (0.48%) while the other effectively doesn't.
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
CRL return calculator
See what $1,000 in Charles River Laboratories International, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.